We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Probing 3CL protease: Rationally designed chemical moieties for COVID‐19.
- Authors
Sharma, Mousmee; Prasher, Parteek; Mehta, Meenu; Zacconi, Flavia C.; Singh, Yogendra; Kapoor, Deepak N.; Dureja, Harish; Pardhi, Dinesh M.; Tambuwala, Murtaza M.; Gupta, Gaurav; Chellappan, Dinesh K.; Dua, Kamal; Satija, Saurabh
- Abstract
GLO:OBD/01dec20:ddr21724-toc-0001.jpg PHOTO (COLOR): . gl The outbreak of the COVID-19 pandemic has already pushed the worldwide morbidity and mortality rates to prodigious proportions, obligating deliberate efforts in identifying novel pharmacophores to manage the pathogenesis and, in addition, to target critical pathways that otherwise, sustain viral viability (Singh, Gupta, Satija, Negi, et al., 2020; Singh, Gupta, Satija, Pabreja et al., 2020). -KETOAMIDE-BASED 3CL PROTEASE INHIBITORS The -ketoamide group presents a potential pharmacophoric profile for targeting the 3CL protease enzyme of COVID-19, as validated by the inhibitory profiles of compounds B 1-4 b (Figure 1). These peptide-appended anilides successfully inhibited SARS-CoV-1 3CL protease via competitive inhibition, while adopting a highly stabilized conformation within the active site loop of the target enzyme. An overview of severe acute respiratory syndrome-coronavirus (SARS-CoV) 3CL protease inhibitors: Peptidomimetics and small molecule chemotherapy.
- Subjects
COVID-19; MOIETIES (Chemistry); SARS virus; SARS-CoV-2; SARS disease; DNA helicases
- Publication
Drug Development Research, 2020, Vol 81, Issue 8, p911
- ISSN
0272-4391
- Publication type
Article
- DOI
10.1002/ddr.21724